Gene therapy for prostate cancer: Where are we now?

Journal of Urology

Volumn 164, Issue 4, 2000, Pages 1121-1136

  Steiner, Mitchell S ^a   Gingrich, Jeffrey R ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

DNA; Gene therapy; Immunotherapy; Prostate; Prostatic neoplasms

Indexed keywords

DNA;

CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; DNA SEQUENCE; DNA TRANSFER; GENE EXPRESSION; GENE THERAPY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SUICIDE GENE;

EID: 0033817636     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67127-3     Document Type: Review

References (147)

1. Cancer statistics, 1999, CA
2. Prostate cancer kills: Strategy to reduce deaths
3. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
4. Is radical prostatectomy primarily a surgical debulking procedure?
5. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years
6. Screening, early detection, and treatment of prostate cancer: A European view
7. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer
8. 'Down staging' with neoadjuvant hormone treatment: The more organ confined prostate cancer (PCa) does not translate into lower PSA failure
9. A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 months post-treatment PSA results
10. Radical prostatectomy alone vs. radical prostatectomy preceded by androgen blockage in cT2b prostate cancer: 24 Month results
11. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer: Initial results
12. Neoadjuvant androgen deprivation therapy and radical prostatectomy for clinically localized prostate cancer
13. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy
14. The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer
15. The challenge of radiation treatment of carcinoma of the prostate
16. Are monotherapy options reasonable for T3 prostate cancer?
17. Adenocarcinoma of the prostate
18. Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate specific antigen
19. Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression
20. Dedifferentiation with time in prostate cancer and the influence of treatment on the course of the disease
21. Molecular genetics of prostate cancer
22. Current challenges of gene therapy for prostate cancer
23. Ex vivo and in vivo gene therapy strategies for prostate cancer: Emerging clinical pharmacology
24. Gene therapy for prostate cancer
25. An expressed-sequence-tag database of the human prostate: Sequence analysis of 1168 cDNA clones
26. Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence
27. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models
28. A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow
29. Biological catalysis by RNA
30. The clinical usefulness of prostate specific antigen: Update 1994
31. Cell proliferation, DNA repair and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation
32. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization
33. Delivery of adenoviral vectors to the prostate for gene therapy
34. Clinical phase I gene therapy trial using BRCA1 retrovirus is safe
35. Viral delivery in a gelatin sponge matrix enhances gene expression and antitumor activity in a murine prostate cancer model
36. The I.M.A.G.E. Consortium: An integrated molecular analysis of genomes and their expression
37. PEDB: The Prostate Expression Database
38. Anti-prostate immunotoxins: Cytotoxicity of E4 antibody-Pseudomonas exotoxin constructs
39. PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis and uterus
40. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance
41. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
42. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
43. Tissue specific expression of a prostate-specific antigen promoter/enhancer in an adenoviral vector used in a human prostate cancer SCID mouse model
44. Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen
45. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer
46. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen
47. Gene therapy vectors for prostate cancer
48. The int-2 gene product acts as an epithelial growth factor in transgenic mice
49. Antisense c-myc retroviral vector suppresses established human prostate cancer
50. Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model
51. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen
52. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
53. Androgen-insensitive prostate-specific gene therapy constructs are inducible with the differentiation agent, phenylbutyrate
54. Expression of osteocalcin in canine metastatic prostate cancer: A ideal prostate cancer animal model for osteocalcin promoter-based toxic gene therapy
55. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate
56. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
57. The future of gene therapy in the treatment of urologic malignancies
58. Molecular characterization of defective antigen processing in human prostate cancer
59. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
60. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma
61. Gene therapy for prostate cancer
62. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
63. Treatment of established renal cell cancer by tumor cells engineered to secrete interleukin-4
64. The value of serum prostate specific antigen determinations before and after radical prostatectomy
65. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
66. Cytoreductive gene therapy for human prostate cancer
67. Gene therapy of cancer: Translational approaches from preclinical studies to clinical implementation
68. High efficiency gene transfer into primary human tumor explants without cell selection
69. Demonstration of a rational strategy for human prostate cancer gene therapy
70. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
71. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth
72. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
73. Metastatic prostate cancer in a transgenic mouse
74. Prostate cancer in a transgenic mouse
75. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model
76. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo
77. Cytokine mediated immuno-gene therapy in rat prostate cancer model
78. Cancer vaccines: The interleukin 2 dosage effect
79. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity
80. Gene therapy approaches in urologic oncology
81. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer
82. Immunologic effects of interleukin-2 (IL-2) gene therapy in prostate cancer (CAP)
83. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens
84. Cellular mucins: Targets for immunotherapy
85. Differential apomucin expression in normal and neoplastic human gastrointestinal tissues
86. Detection of the MUC2 apomucin tandem repeat with a mouse monoclonal antibody
87. Immune recognition of human colonic-tumour-associated MUC-2 mucins using an anti-peptide antibody
88. PSA-encoding adenovirus induces potent antitumor immunity in a mouse prostate tumor model
89. Interleukin-12 gene therapy induces cell death through induction of FAS/FAS ligand-mediated death in metastatic mouse prostate cancer
90. Gene therapy of prostate cancer with adenovirus-mediated fas ligand (FasL) expression
91. Gene therapy: The future is here - A guide to the practicing urologist
92. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene
93. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
94. Adenoviral-mediated expression of wildtype p16INK4A inhibits prostate cancer cell growth in vitro and in vivo
95. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: A preclinical study
96. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21(WAF1/CIP1) and p16(CDKN4)) in human prostate cancers
97. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
98. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
99. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
100. Evaluation of the mechanisms of anti-tumorigenic effects of the AdWTp53 on DU145 cells derived tumors in nude mice
101. Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches
102. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
103. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
104. Deletional, mutational and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer
105. Concomitant presence of p16/cyclin-dependent kinase 4 and cyclin D/cyclin-dependent kinase 4 complexes in LNCaP prostatic cancer cell line
106. Role of the p16 tumor suppressor gene in cancer
107. Expression of tumor suppressor gene p16 effectively inhibits the growth of prostate cancer cells
108. Adenoviral vector containing wild type p16 suppresses prostate cancer growth and prolongs survival
109. Molecular insights into altered cell cycle regulation and genitourinary malignancy
110. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells
111. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2
112. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
113. Prostate-specific amplification of expanded polyglutamine expression: A novel approach for cancer gene therapy
114. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
115. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
116. Enhanced apoptosis of prostate cancer cells by adenoviral hammerhead ribozyme mediated disruption of bcl-2
117. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer
118. Expression of the translation initiation factor eF4E modulates prostate tumor vascularization
119. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
120. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells
121. Enhancement of bystander prostate cancer cell killing by the utilization of genetically engineered bone stromal cells that confer either cytosine deaminase or thymidine kinase gene
122. In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors
123. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics
124. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
125. An uncertain role for p53 gene alterations in human prostate cancers
126. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer
127. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
128. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
129. Ablation of murine prostate utilizing Ad-OC-TK/GCV treatment: A potential gene therapy strategy for the treatment of benign prostatic hyperplasia (BPH)
130. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate and breast cancer
131. Treatment of prostate cancer with Ad5CMV-p53 as a single agent or in combination with DNA damaging agents
132. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer
133. Enhanced transgene delivery by adenovirus vectors in the presence of paclitaxel; potential mechanistic synergy between pharmaceutical and genetic therapies
134. Cytosine deaminase (CDA) adenoviral vector (ADV) and administration of the non toxic prodrug 5-fluorocytosine (5FC) used for therapy sensitization (TS) of prostate cancer cells
135. Natural killer cells induced by herpes simplex virus thymidine kinase gene transduction and ganciclovir therapy are enhanced by interleukin-12 gene therapy in an orthotopic model of mouse prostate cancer
136. Recombinant DNA and Gene Transfer. Office of Recombinant DNA Activities, National Institutes of Health
137. Bioactivity of autologous irradiated prostate cancer vaccines generated by ex vivo GM-CSF gene transfer
138. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
139. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
140. LN-CaP model of human prostatic carcinoma
141. Clinical activity and broken immunologic tolerance from ex vivo GM-CSF gene transduced prostate cancer vaccines
142. AD-p53 intraprostatic gene therapy preceding radical prostatectomy (RP): An in vivo model for targeted therapy development
143. Effect of interleukin-2 (IL-2) gene therapy on prostate specific antigen in patients undergoing neoadjuvant or adjuvant gene therapy for prostate cancer
144. A phase I study of recombinant vaccinia virus (RV) that expresses prostate specific antigen (PSA) in adult patients with adenocarcinoma of the prostate
145. A phase I trial of recombinant vaccinia virus, PROSTVAC that expresses prostate specific antigen (rV-PSA) as a vaccine in men with advanced prostate cancer
146. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
147. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration